#drug maker

[abvhv]

Bankrupt drugmaker Mallinckrodt considers sale of opioid business - Abvhv.org

Bankrupt drugmaker Mallinckrodt considers sale of opioid business: The Wall Street Journal reported on Monday, citing individuals

[hindinewsnowfan]

फार्मा सेक्टर को आत्मनिर्भर बनाने के लिए मोदी सरकार ने जारी किए 4 नए गाइडलाइन

फार्मा सेक्टर को आत्मनिर्भर बनाने के लिए मोदी सरकार ने जारी किए 4 नए गाइडलाइन

[ad_1]

घरेलू मैन्युफैक्चरिंग को बढ़ावा देने के लिए सरकार ने जारी किए दिशानिर्देश सरकार ने सोमवार को देश में बल्क ड्रग (Bulk Drug) के घरेलू विनिर्माण को बढ़ावा देनेऔर मेडिकल डिवाइस पार्कों (medical device parks) के विकास के लिए चार योजनाओं के…

View On WordPress

[alphst]

Neos Therapeutics (NASDAQ: NEOS): Q4 2019 Earnings Snapshot

— Neos Therapeutics Inc. (NASDAQ: NEOS) reported a fourth-quarter 2019 loss of $0.07 per share versus a loss of $0.03 per share expected.

— Total product revenue grew by 9.1% to $16.8 million versus $20.57 million expected.

— The bottom line reflected the evolution of the commercial strategy and the company’s focus on both operational productivity and expense management.

— The company…

View On WordPress

[alphst]

Eagle Pharmaceuticals (NASDAQ: EGRX): Q4 2019 Earnings Snapshot

Eagle Pharmaceuticals (NASDAQ: EGRX): Q4 2019 Earnings Snapshot

— Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) reported its fourth-quarter 2019 adjusted earnings of $0.48 per share versus $0.46 per share expected.

— Total revenue fell by 14% year-over-year to $48.3 million versus $49.07 million expected. The top line was hurt by lower product sales of Bendeka and Ryanodex and lower argatroban royalty revenue.

— R&D expense jumped by 92% largely due to…

View On WordPress

[alphst]

Endo International (NASDAQ: ENDP): Q4 2019 Earnings Snapshot

Endo International (NASDAQ: ENDP): Q4 2019 Earnings Snapshot

— Endo International plc (NASDAQ: ENDP) reported its fourth-quarter 2019 adjusted earnings of $0.74 per share versus $0.57 per share expected.

— Total revenues declined by 3% to $764.8 million versus $731.43 million expected. This was due to competitive pressures in the Generic Pharmaceuticals segment and the Established Products portfolio of the Branded Pharmaceuticals segment.

— Branded…

View On WordPress

[alphst]

Zoetis (NYSE: ZTS): Q4 2019 Earnings Snapshot

Zoetis (NYSE: ZTS): Q4 2019 Earnings Snapshot

— Zoetis Inc. (NYSE: ZTS) reported its fourth-quarter 2019 adjusted earnings of $0.92 per share versus $0.88 expected.

— Revenues grew 7% to $1.7 billion versus $1.64 billion expected. On an operational basis, revenue, excluding the impact of foreign exchange, increased by 9%.

— The US segment revenue rose by 6% as growth in key dermatology portfolio across both the Apoquel and Cytopoint…

View On WordPress

[alphst]

Teva Pharmaceutical (TEVA) swings to profit in Q4, beats estimates

Teva Pharmaceutical (TEVA) swings to profit in Q4, beats estimates

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) swung to a profit in the fourth quarter of 2019 from a loss last year, helped by lower costs and expenses as well as a tax benefit. The results exceeded analysts’ expectations. Further, the company guided full-year guidance in-line with the consensus view.

Net income was $110 million compared to a loss of $2.94 billion in the previous year…

View On WordPress

[alphst]

Bristol-Myers Squibb (BMY) slips to a loss in Q4 but beats estimates

Bristol-Myers Squibb (BMY) slips to a loss in Q4 but beats estimates

Bristol-Myers Squibb Company (NYSE: BMY) slipped to a loss in the fourth quarter of 2019 from a profit last year, due to the amortization of acquired intangible assets related to the Celgene purchase. However, the results exceeded analysts’ expectations. Further, the company issued earnings and revenue guidance for the full year 2020 that matched the consensus view.

Net loss was $1.06 billion…

View On WordPress